Tremelimumab is an antibody directed against cytotoxic T lymphocyte–associated antigen-4 (CTLA4) and is similar to ipilimumab.
In several pivotal phase III trials, ipilimumab has been shown to improve overall survival among patients with metastatic melanoma. In this Phase III study of the cytotoxic T lymphocyte–associated antigen-4–blocking monoclonal antibody tremelimumab, 655 patients were randomly assigned to tremelimumab (15 mg/kg once every 90 days) or standard chemotherapy (dacarbazine or temozolomide).
The final study analysis was performed after 534 deaths had occurred. Median overall survival was 12.6 months (95% confidence interval, 10.8–14.3) with tremelimumab and 10.7 months (95% CI, 9.36–11.96) with chemotherapy (hazard ratio, 0.88; P=0.127). The objective response rates were 10.7% and 9.8% in the tremelimumab and chemotherapy groups, respectively, but …
Reviewing Author
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)